Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have achieved at least stable disease on first-line chemotherapy.
Epistemonikos ID: 78b2a719fe00e5612cd37a79bc951a82ab86a185
First added on: Jul 16, 2020